Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain?

Current Opinion in Hematology

Volumn 18, Issue 3, 2011, Pages 158-165

  McGann, Patrick T ^a   Ware, Russell E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

global health; hydroxyurea; mortality; sickle cell anemia

Indexed keywords

HYDROXYUREA; PENICILLIN G; PLACEBO;

ACUTE CHEST SYNDROME; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CARCINOGENESIS; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HEMOGLOBIN SC DISEASE; HEMOGLOBIN SD DISEASE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; LEUKEMIA; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAIL PIGMENTATION; NEUTROPENIA; PAIN; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOCYTOPENIA; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SKIN ULCER; TREATMENT DURATION; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; HUMANS; HYDROXYUREA;

EID: 79955011693     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834521dd     Document Type: Article

References (54)

1. Odame I. Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med 2010; 38 (4 Suppl):S571-S575.
2. Hassell KL Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010; 38 (4 Suppl):S512-S521.
3. Conley CL, Weatherall DJ, Richardson SN, et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 1963; 21:261-281.
4. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr 1990; 37:1-31.
5. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74:652-656. (Pubitemid 14054015)
6. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332:1132-1136.
7. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452-2466. (Pubitemid 44903749)
8. Kennedy BJ, Yarbro JW. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. J Am Med Assoc 1966; 195:1038-1043.
9. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-805. (Pubitemid 24359288)
10. Elford HL Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 1968; 33:129-135.
11. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79:2555-2565.
12. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94:1550-1554. (Pubitemid 29411304)
13. Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 2009; 52:609-615.
14. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106:2269-2275. (Pubitemid 41510795)
15. Wang W, Thompson B. Hydroxyurea treatment of infants with sickle cell anemia: results of the BABY HUG study. ASPHO Annual Meeting Abstract. Pediatr Blood Cancer 2010; 54:787.
16. Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction; what doesn't kill red blood cells makes them stronger. Exp Hematol 2008; 36:1057-1072.
17. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111:231-239. (Pubitemid 36105922)
18. Cokic VP, Andric SA, Stojilkovic SS, et al. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 2008; 111:111 7-1123. (Pubitemid 351213390)
19. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci 2001; 98:1847-1852. (Pubitemid 32165586)
20. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300-5311.
21. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 2010; 24:199-214.
22. Steinberg MH, Barton F, Castro O, etal. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc 2003; 289:1645-1651. (Pubitemid 37430269)
23. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103:2039-2045. (Pubitemid 38326218)
24. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88:1960-1964. (Pubitemid 26307897)
25. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged admin-istration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-centertrial (LaSHS). Blood 2010; 115:2354-2363.
26. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:131 7-1322.
27. Lanzkron S, Strouse JJ, Wilson R, etal. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148:939-955. (Pubitemid 351860826)
28. Strouse JJ, Lanzkron S, Beach MC, etal. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008; 122:1332-1342.
29. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932-938. (Pubitemid 351860825)
30. Thompson BW, Miller ST, Rogers ZR, etal. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer 2010; 54:250-255.
31. Powars DR, Chan LS, Hiti A, etal. Outcome of sickle cell anemia: a4-decade observational study of 1056 patients. Medicine 2005; 84:363-376. (Pubitemid 41668935)
32. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-1644.
33. Hankins JS, Helton KJ, McCarville MB, et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 2008; 50:293-297.
34. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007; 110:1043-1047. (Pubitemid 47267446)
35. Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med 1969; 281:923-926.
36. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985; 76:392-397. (Pubitemid 15242503)
37. Whitten CF, Younes AA. A comparative study of renal concentrating ability in children with sickle cell anemia and in normal children. J Lab Clin Med 1960; 55:400-415.
38. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr 2010; 156:66-70.
39. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med 1990; 150:501-504. (Pubitemid 20122000)
40. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol 2000; 63:205-221.
41. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010; 85:403-408.
42. Lobo C, Hankins JS, Moura P, Pinto JC. Hydroxyurea therapy reduces mortality among children with sickle cell disease. ASH Annual Meeting Abstracts. Blood 2010; 116:843a.
43. Weinlich G, Schuler G, Greil R, et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39:372-374. (Pubitemid 28367320)
44. Oppenheim JJ, Fishbein WN. Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Cancer Res 1965; 25:980-985.
45. Ziegler-Skylakakis K, Schwarz LR, Andrae U. Microsome-and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat Res 1985; 152 (2-3):225-231. (Pubitemid 16198555)
46. Murphy ML, Chaube S. Preliminary survey of hydroxyurea (Nsc-32065) as a teratogen. Cancer Chemother Rep 1964; 40:1-7.
47. Sakano K, Oikawa S, Hasegawa K, Kawanishi S. Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res 2001; 92:1166-1174. (Pubitemid 33133485)
48. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97:3628-3632.
49. Flanagan JM, Howard TA, Mortier N, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res 2010; 698:38-42.
50. McGann PT, Howard TA, Flanagan JM, et al. Chromosome damage and repair in children with sickle cell anemia and long-term hydroxyurea exposure. ASPHO Annual Meeting Abstract. Pediatr Blood Cancer (in press).
51. Hankins JS, Aygun B, Wang W, et al. From infancy to adolescence: over a decade of continuous hydroxyurea therapy in sickle cell anemia. ASPHO Annual Meeting Abstract. Pediatr Blood Cancer 2010; 54:790.
52. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115:4331-4336.
53. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447-3452.
54. Weatherall D, Hofman K, Rodgers G, et al. A case for developing North-South partnerships for research in sickle cell disease. Blood 2005; 105:921-923. (Pubitemid 40170855)